Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsSARS-CoV-2-naı̈ve individuals achieved levels similar to mild natural infection after the first vaccination; a second dose generated levels approaching severe natural infection.
[ACS Nano]
6445212 TRLBDLKW items 1 apa 0 default asc 1 163843 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-9be36f102a3a9766532943e821e87821%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22TRLBDLKW%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ibarrondo%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-23%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EIbarrondo%2C%20F.%20J.%2C%20Hofmann%2C%20C.%2C%20Fulcher%2C%20J.%20A.%2C%20Goodman-Meza%2C%20D.%2C%20Mu%2C%20W.%2C%20Hausner%2C%20M.%20A.%2C%20Ali%2C%20A.%2C%20Balamurugan%2C%20A.%2C%20Taus%2C%20E.%2C%20Elliott%2C%20J.%2C%20Krogstad%2C%20P.%2C%20Tobin%2C%20N.%20H.%2C%20Ferbas%2C%20K.%20G.%2C%20Kitchen%2C%20S.%20G.%2C%20Aldrovandi%2C%20G.%20M.%2C%20Rimoin%2C%20A.%20W.%2C%20%26amp%3B%20Yang%2C%20O.%20O.%20%282021%29.%20Primary%2C%20Recall%2C%20and%20Decay%20Kinetics%20of%20SARS-CoV-2%20Vaccine%20Antibody%20Responses.%20%3Ci%3EACS%20Nano%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsnano.1c03972%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsnano.1c03972%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DTRLBDLKW%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Primary%2C%20Recall%2C%20and%20Decay%20Kinetics%20of%20SARS-CoV-2%20Vaccine%20Antibody%20Responses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20Javier%22%2C%22lastName%22%3A%22Ibarrondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hofmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20A.%22%2C%22lastName%22%3A%22Fulcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Goodman-Meza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Mu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20Ann%22%2C%22lastName%22%3A%22Hausner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayub%22%2C%22lastName%22%3A%22Ali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arumugam%22%2C%22lastName%22%3A%22Balamurugan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellie%22%2C%22lastName%22%3A%22Taus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Elliott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Krogstad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%20H.%22%2C%22lastName%22%3A%22Tobin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathie%20G.%22%2C%22lastName%22%3A%22Ferbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20G.%22%2C%22lastName%22%3A%22Kitchen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grace%20M.%22%2C%22lastName%22%3A%22Aldrovandi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20W.%22%2C%22lastName%22%3A%22Rimoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Otto%20O.%22%2C%22lastName%22%3A%22Yang%22%7D%5D%2C%22abstractNote%22%3A%22Studies%20of%20two%20SARS-CoV-2%20mRNA%20vaccines%20suggested%20that%20they%20yield%20%5Cu223c95%25%20protection%20from%20symptomatic%20infection%20at%20least%20short-term%2C%20but%20important%20clinical%20questions%20remain.%20It%20is%20unclear%20how%20vaccine-induced%20antibody%20levels%20quantitatively%20compare%20to%20the%20wide%20spectrum%20induced%20by%20natural%20SARS-CoV-2%20infection.%20Vaccine%20response%20kinetics%20and%20magnitudes%20in%20persons%20with%20prior%20COVID-19%20compared%20to%20virus-na%5Cu0131%5Cu0308ve%20persons%20are%20not%20well-defined.%20The%20relative%20stability%20of%20vaccine-induced%20versus%20infection-induced%20antibody%20levels%20is%20unclear.%20We%20addressed%20these%20issues%20with%20longitudinal%20assessments%20of%20vaccinees%20with%20and%20without%20prior%20SARS-CoV-2%20infection%20using%20quantitative%20enzyme-linked%20immunosorbent%20assay%20%28ELISA%29%20of%20anti-RBD%20antibodies.%20SARS-CoV-2-na%5Cu0131%5Cu0308ve%20individuals%20achieved%20levels%20similar%20to%20mild%20natural%20infection%20after%20the%20first%20vaccination%3B%20a%20second%20dose%20generated%20levels%20approaching%20severe%20natural%20infection.%20In%20persons%20with%20prior%20COVID-19%2C%20one%20dose%20boosted%20levels%20to%20the%20high%20end%20of%20severe%20natural%20infection%20even%20in%20those%20who%20never%20had%20robust%20responses%20from%20infection%2C%20increasing%20no%20further%20after%20the%20second%20dose.%20Antiviral%20neutralizing%20assessments%20using%20a%20spike-pseudovirus%20assay%20revealed%20that%20virus-na%5Cu0131%5Cu0308ve%20vaccinees%20did%20not%20develop%20physiologic%20neutralizing%20potency%20until%20the%20second%20dose%2C%20while%20previously%20infected%20persons%20exhibited%20maximal%20neutralization%20after%20one%20dose.%20Finally%2C%20antibodies%20from%20vaccination%20waned%20similarly%20to%20natural%20infection%2C%20resulting%20in%20an%20average%20of%20%5Cu223c90%25%20loss%20within%2090%20days.%20In%20summary%2C%20our%20findings%20suggest%20that%20two%20doses%20are%20important%20for%20quantity%20and%20quality%20of%20humoral%20immunity%20in%20SARS-CoV-2-na%5Cu0131%5Cu0308ve%20persons%2C%20while%20a%20single%20dose%20has%20maximal%20effects%20in%20those%20with%20past%20infection.%20Antibodies%20from%20vaccination%20wane%20with%20kinetics%20very%20similar%20to%20that%20seen%20after%20mild%20natural%20infection%3B%20booster%20vaccinations%20will%20likely%20be%20required.%22%2C%22date%22%3A%222021-06-23%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1021%5C%2Facsnano.1c03972%22%2C%22ISSN%22%3A%221936-0851%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsnano.1c03972%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-24T16%3A24%3A40Z%22%7D%7D%5D%7D
Ibarrondo, F. J., Hofmann, C., Fulcher, J. A., Goodman-Meza, D., Mu, W., Hausner, M. A., Ali, A., Balamurugan, A., Taus, E., Elliott, J., Krogstad, P., Tobin, N. H., Ferbas, K. G., Kitchen, S. G., Aldrovandi, G. M., Rimoin, A. W., & Yang, O. O. (2021). Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. ACS Nano. https://doi.org/10.1021/acsnano.1c03972 Cite
